What is the purpose of the Angelman syndrome study?

The purpose of the study is to look at the safety, tolerability, and efficacy of NNZ-2591 in the treatment of children with Angelman syndrome.

This study investigates an oral medication called “NNZ-2591”, which aims to improve the impaired connections and signalling between brain cells that are involved in Angelman syndrome. The study medication is experimental.

What does the study involve?

Participation in the study will be required for approximately 19 weeks, with a combination of in-clinic, remote, and telehealth consultations. An in-home nurse will also visit your house to check on the participant and administer a number of assessments.

To ease the burden of travel on families, an in-home nurse will be available to assist with telehealth/remote visits. At a time convenient to yourselves, the in-home nurse will visit your home and conduct a number of the required study assessments. This has been included in the study design to make it easier for your family to participate in the study and promote inclusion, without compromising on the data that needs to be collected at each visit.

Participants in the Angelman study will need to:

Is there a cost?

There is no cost to participate in this clinical trial.

Reimbursement is available for reasonable* travel and incidental costs incurred attending your clinic visits.

* In accordance with ATO schedules on reasonable allowances (Tax Determination 2021/16)

More details on this can be found by clicking through to our Resources page here, or by contacting ASAA at

Who is eligible for this study?

Potential participants must:

Specific details on the eligibility criteria can be found at www.clinicaltrials.gov

The clinical team managing the study at one of the participating sites will determine if your child is eligible to enrol. For more information, please speak with one of the participating site teams.